EXPLANATORY STATEMENT
NATIONAL HEALTH ACT 1953
NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2020 (No. 1)
PB 10 of 2020
Authority
This legislative instrument, made under section 85B of the National Health Act 1953 (the Act) amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) (the Principal Determination).
Subsections 85B(2), (3) and (4) of the National Health Act 1953 (the Act) provide for the Minister to determine, respectively, determined prices, claimed prices and the circumstances in which the Commonwealth will pay a special patient contribution. The Principal Determination contains determinations of these matters.
Variation and revocation
Unless there is an express power to revoke or vary PB 109 of 2010 cited in this Instrument and explanatory statement, subsection 33(3) of the Acts Interpretation Act 1901 is relied upon to revoke or vary PB 109 of 2010.
Purpose
The Act provides for the Minister and the responsible person to agree a price that is taken to be the appropriate maximum price of a brand of a pharmaceutical item for the purposes of Part VII of the Act (section 85AD). Section 85B of the Act applies if the Minister and the responsible person have been unable to reach an agreement on a price for the pricing quantity. Whether or not an agreement is made for the pricing quantity, section 85B also applies if the responsible person is dissatisfied with the proportional ex-manufacturer prices that will apply to other pack quantities.
Subsection 85B(2) provides that the Minister may determine, by reference to the pricing quantity of a brand of a pharmaceutical item, an amount that is taken to be the appropriate maximum price of the brand for the purposes of Part VII of the Act. This is termed the ‘Determined Price’ in this Determination.
Subsection 85B(3) provides that the Minister may determine, by reference to a pack quantity of a brand of the pharmaceutical item, an amount that is taken to be the price claimed by the responsible person for the pack quantity of the brand, for the purposes of Part VII of the Act. This is termed the ‘Claimed Price’ in this Determination.
The Determined Price is the approved ex-manufacturer price and is used as the basis for working out the Commonwealth price for the brand of the pharmaceutical item (section 98B of the Act); for pack quantities other than the pricing quantity, the proportional ex-manufacturer price is used as the basis. Approved pharmacists are entitled to payment from the Commonwealth equal to the Commonwealth price less the applicable patient co-payment (section 99 of the Act).
The difference between the responsible person’s Commonwealth price for a pack quantity (ie, the price that would be the Commonwealth price if the responsible person’s claimed price had become the approved ex-manufacturer price or the proportional ex-manufacturer price for that pack quantity) and the Commonwealth price for the pack quantity is defined in subsection 85B(5) of the Act as the special patient contribution. An approved pharmacist may charge a patient an amount equal to the special patient contribution, in addition to any other amount that may be charged (subsection 87(2A) of the Act).
Subsection 85B(4) of the Act provides that the Minister may determine the circumstances in which the Commonwealth is to pay the special patient contribution for a brand. In such cases, the Commonwealth payment to the pharmacist is increased by the amount of the special patient contribution (subsection 99(2AA) of the Act) and the pharmacist may not charge the patient this amount (subsection 87(2A) of the Act).
The purpose of making subsection 85B(4) determinations is to enable patients for whom the base-priced brands (the ones without a special patient contribution) are not suitable, to obtain the higher priced brand (the one with the special patient contribution) without the need to pay the higher price. In such cases the Commonwealth pays the special patient contribution.
This instrument (the Amending Determination) amends the Principal Determination by increasing the brand premium to multiple brands of pharmaceutical items in addition to adding a new brand premium to nine brands of nine pharmaceutical items. It also reinstates one brand premium to one pharmaceutical item in addition to removing one brand of one pharmaceutical item that will no longer be PBS listed on
1 February 2020.
Consultation
This determination affects certain responsible persons with medicines listed on the PBS. Before a pharmaceutical benefit is listed on the PBS, and from time to time thereafter, price negotiations occur between the responsible person and the Minister for the purpose of reaching a price agreement for section 85AD of the Act. If the Minister and the responsible person do not agree on a price, further consultation occurs with the responsible person, and thereafter the Minister determines the price that will be the approved ex-manufacturer price for the brand. The Minister also determines the corresponding price claimed by the responsible person which is used to calculate the special patient contribution that will apply to the brand.
Responsible persons affected by this determination made submissions about what claimed price the Minister should determine in relation to each brand. Responsible persons were advised of the delegate’s intention to determine in accordance with the requests they had made. No further response from the affected responsible persons was received in response to this notification.
For Ranitidine, the changes made by this determination are consistent with the request, made by the responsible person, for the removal of this brand from the PBS with effect from 1 February 2020. As a result, further consultation with the responsible person affected by this determination was unnecessary.
No additional consultation with experts was undertaken regarding this determination because consultation with the affected responsible persons which informed the making of this determination drew on knowledge of persons with relevant expertise.
A provision by provision description of the Amending Determination is contained in the Attachment.
This Determination commences on 1 February 2020.
This Determination is a legislative instrument for the purposes of the Legislation Act 2003.
ATTACHMENT
PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2020 (No. 1)
(PB 10 of 2020)
Section 1 Name of Determination
This section provides that the Determination is the National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1) and may also be cited as PB 10 of 2020.
Section 2 Commencement
This section provides that the Determination commences on 1 February 2020.
Section 3 Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
This section provides that Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1 Amendments commencing 1 February 2020
Schedule 1 sets out the amendments to the Principal Determination which commence on 1 February 2020.
SUMMARY OF CHANGES
SCHEDULE 1
| ||
Brands with increased brand premiums | ||
Cefaclor | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Ceclor |
| Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL | Ceclor |
| Tablet (sustained release) 375 mg (as monohydrate) | Ceclor CD |
Levonorgestrel with Ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Levlen ED |
Telmisartan | Tablet 40 mg | Micardis |
| Tablet 80 mg | Micardis |
Telmisartan with amlodipine | Tablet 40 mg‑5 mg (as besilate) | Twynsta |
| Tablet 40 mg‑10 mg (as besilate) | Twynsta |
| Tablet 80 mg‑5 mg (as besilate) | Twynsta |
| Tablet 80 mg‑10 mg (as besilate) | Twynsta |
Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | Micardis Plus 40/12.5 mg |
| Tablet 80 mg‑12.5 mg | Micardis Plus 80/12.5 mg |
| Tablet 80 mg‑25 mg | Micardis Plus 80/25 mg |
Brands with a new brand premium | ||
Dicloxacillin | Capsule 250 mg (as sodium) | Distaph 250 |
| Capsule 500 mg (as sodium) | Distaph 500 |
Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Dothep 25 |
| Tablet containing dosulepin hydrochloride 75 mg | Dothep 75 |
Hydrocortisone | Tablet 4 mg | Hysone 4 |
| Tablet 20 mg | Hysone 20 |
Hydromorphone | Injection containing hydromorphone hydrochloride 2 mg in 1 mL | Dilaudid |
| Injection containing hydromorphone hydrochloride 10 mg in 1 mL | Dilaudid-HP |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Endone |
Reinstatement of a brand premium | ||
Methyldopa | Tablet 250 mg (as sesquihydrate) | Aldomet |
Deletion of brand | ||
Ranitidine | Tablet, effervescent, 150 mg (as hydrochloride) | Zantac |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statement of Compatibility with Human Rights
Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011
National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1) (PB 10 of 2020)
This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.
Overview of the Legislative Instrument
This legislative instrument, made under section 85B of the National Health Act 1953 (the Act), amends the National Health (Price and Special Patient Contribution) Determination 2010 (the Principal Determination), which provides for price determinations in relation to brands of pharmaceutical items listed on the Pharmaceutical Benefits Scheme (PBS) for which the Minister and the responsible person have not been able to make a price agreement. It also provides for the circumstances in which the Commonwealth will pay the special patient contribution resulting from these price determiations. This instrument (the Amending Determination) amends the Principal Determination by increasing the brand premium to multiple brands of pharmaceutical items in addition to adding a new brand premium to nine brands of nine pharmaceutical items. It also reinstates one brand premium to one pharmaceutical item in addition to removing one brand of one pharmaceutical item that will no longer be PBS listed on 1 February 2020.
Human rights implications
This legislative instrument engages Articles 2 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.
The PBS is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines. The recommendatory role of the Pharmaceutical Benefits Advisory Committee (PBAC) ensures that decisions about subsidised access to medicines on the PBS are evidence-based.
Conclusion
This Legislative Instrument is compatible with human rights because it advances the protection of human rights.
Thea Daniel
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health